Zimmer Biomet Holdings Inc
ZBH - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$21.17B
Close$
Earnings Call Q2 2025
August 7, 2025 - AI Summary
Q2 Performance & Growth Outlook: Zimmer Biomet reported a 2.8% organic constant currency revenue growth in Q2 2025, with positive contributions from the U.S. Hips (up 5.2%) and Knees (up 1.7%). For the full year, the company raised its organic revenue growth guidance to 3.5%-4.5%, previously 3%-5%, and expects Paragon 28 to contribute an additional 270 basis points.
Adjusted Earnings Guidance: The company increased its adjusted EPS forecast for 2025 to $8.10-$8.30, from $7.90-$8.10, reflecting strong operational efficiencies, reduced tariff impacts, and favorable foreign exchange conditions. This suggests a commitment to profitability in a challenging market environment.
Strategic Acquisitions: The acquisition of Monogram Technologies was highlighted as a pivotal event for the company, aimed at advancing Zimmer Biomet’s robotics capabilities. The deal is expected to be neutral to adjusted EPS between 2025 and 2027, with potential revenue contributions beginning in 2027.
Exclusive for Stockcircle Pro members
Sign up
$275.34
149.9% upside
Current Fair Value
149.9% upsideUndervalued by 149.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $21.17 Billion |
|---|---|
| Enterprise Value | $28.24 Billion |
| Annual dividend | $0.96 |
| Dividend yield | 1.02% |
| Earnings per Share | $3.56 |
| Beta | 0.49 |
| Outstanding Shares | 192,200,000 |
Return
| Return on Equity | 6.39% |
|---|---|
| Return on Assets | 3.54% |
| Return on Invested Capital | 6.81% |
Valuation & Multiples
| P/E Ratio | 22.89 |
|---|---|
| PEG | - |
| Price to Sales | 2.5 |
| Price to Book Ratio | 1.69 |
| Enterprise Value to Revenue | 3.32 |
| Enterprise Value to EBIT | 20.97 |
| Enterprise Value to Net Income | 35 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | 0.59 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$1.88
Consensus analyst estimateRevenue Estimate
$2.04 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 9, 2027
EPS Estimate
$2.50
Consensus analyst estimateRevenue Estimate
$2.29 B
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 95.53% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.59%▼ 100.09% |
|---|---|
| Total Invested | $438.88M▼ 97.45% |
| Investors Holding | 318▼ 616.00% |
About Zimmer Biomet Holdings Inc
17,000 employees
CEO: Bryan Hanson
Zimmer Biomet Holdings, Inc., along with its various subsidiaries, is a prominent player in the global musculoskeletal healthcare industry, providing its specialized solutions across the Americas, Europe, the Middle East, Africa, and the...